Trial · NCT03292016
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Maximum Observed Plasma Concentration (Cmax) | Day 1 | Dose normalized maximum observed plasma concentration (Cmax) |
| Primary | Observed Time of the Maximum Concentration (Tmax) | Day 1 | Time from dosing to Cmax, observed by inspection of individual subject plots of plasma concentration versus time. |
| Primary | Area Under the Concentration- Time Curve (AUC Last) | Day 1 | area under the concentration-time curve from time zero to the last measurable plasma concentration-time curve using the linear up log down trapezoidal rule. |
| Primary | Area Under the Concentration- Time Curve (AUC Inf) | Day 1 | area under the concentration-time curve from time zero extrapolated to infinity using the linear up log down trapezoidal rule. |
| Primary | Mean Residence Time (MRT) | Day 1 | Mean residence time during one dosing interval calculated using the following equation: MRT = AUMCinf/AUC inf. AUMCinf is the area under the first moment (time.plasma concentration vs. time) curve. |
| Primary | Metabolite/Parent (M/P) Drug Concentration Ratio -Cmax | Day 1 | Metabolite (apomorphine sulfate) to Parent exposure ratio, Cmax, corrected for molecular weight differences. |
| Primary | Apparent Total Clearance of the Drug From Plasma After Oral Administration (CL/F) | Day 1 | Apparent total clearance of the drug from plasma extravascular administration, calculated as Dose/AUCinf. |
| Primary | Apparent Volume of Distribution After Non-intravenous Administration (V/F) | Day 1 | Apparent volume of distribution after extravascular administration, calculated as Dose/(AUCinf \* λz). |
| Primary | Terminal-phase Half-life (t½) | Day 1 | Terminal phase half-life, as calculated by the following equation: t½ = ln(2)/λz. |
| Primary | Terminal-phase Rate Constant ( λz) | Day 1 | Apparent terminal elimination rate constant, determined by log linear regression of the plasma concentration versus time data that was judged to be in the log-linear elimination phase. At least 3 data points in the terminal phase will be used in the determination of the rate constant. |
| Primary | Metabolite/Parent (M/P) Drug Concentration Ratio -AUC Last | Day 1 | Metabolite (apomorphine sulfate) to Parent exposure ratio, AUClast, corrected for molecular weight differences. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03292016/registered